# Circulating Red Blood Cell Based Nanosensors for Continuous, Real-Time Drug Monitoring

> **NIH NIH R01** · NORTHEASTERN UNIVERSITY · 2020 · $211,086

## Abstract

ABSTRACT
Nanosensor technology for continuous monitoring of proteins in vivo would enable researchers to track the
dynamics of biomolecule expression as it pertains to disease pathogenesis or predicting therapeutic efficacy,
with results available in real-time. An example where this diagnostic ability would be groundbreaking is in the
context of understanding cytokine release syndrome (CRS). CRS is a systemic inflammatory response that
arises when the immune system is overstimulated, leading to extreme toxic events such as multiple organ
dysfunction1. There is now increasing evidence to suggest that the development of severe cases of COVID-19
can be attributed to onset of CRS. It has been revealed that serum levels of cytokines like IFNγ, IL-6, sIL-2Rα,
and IL-10 can be significantly elevated in patients with severe CRS, before the apparent onset of severe
symptoms. However, the use of cytokines as biomarkers of CRS would require a rapid, minimally invasive
diagnostic assay, which is currently unavailable, slowing animal studies of COVID-19/CRS. Recently published
research from the Clark laboratory has demonstrated a proof-of-concept DNA-based sensor for minimally
invasive detection of IFNγ, one of the cytokines that has been proposed as a biomarker for predicting the
potential for onset of severe CRS. This design was inspired by advances in DNA nanotechnology, which enable
researchers to create functional nanostructures with site-specific modifications based on the complementary
base-pairing rules of DNA. The open or closed state of the sensor could be determined through differential
signals as detected with optical imaging. Drawing from recent advances in DNA origami design and stabilization
technology, we hypothesize that we can improve on this work and produce a robust platform for optical
monitoring of IFNγ in real-time by (1) enhancing the rigidity of our DNA platform and (2) deploying protection
strategies to ionically stabilize the construct in biological solutions. This project aims to advance current analytical
strategies for immunological diagnostics by providing researchers with a powerful tool to probe biomolecule
dynamics toward in vivo use with existing optical imaging platforms. The one-year project will result in a robust
tool developed for animal research. The goal will be to commercialize and distribute the sensor for COVID-19
studies, as well as other immune system research.

## Key facts

- **NIH application ID:** 10174441
- **Project number:** 3R01EB024186-03S1
- **Recipient organization:** NORTHEASTERN UNIVERSITY
- **Principal Investigator:** Heather A Clark
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $211,086
- **Award type:** 3
- **Project period:** 2018-02-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10174441

## Citation

> US National Institutes of Health, RePORTER application 10174441, Circulating Red Blood Cell Based Nanosensors for Continuous, Real-Time Drug Monitoring (3R01EB024186-03S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10174441. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*